Neumora Therapeutics, Inc. (NMRA)
0.347
-0.02
(-5.40%)
USD |
NASDAQ |
Nov 19, 16:00
0.35
0.00 (0.00%)
After-Hours: 20:00
Neumora Therapeutics Enterprise Value : 33.39M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 33.39M |
| November 18, 2026 | 37.13M |
| November 17, 2026 | 31.03M |
| November 16, 2026 | 37.64M |
| November 13, 2026 | 48.84M |
| November 12, 2026 | 49.62M |
| November 11, 2026 | 57.17M |
| November 10, 2026 | 55.96M |
| November 09, 2026 | 59.60M |
| November 06, 2026 | 62.88M |
| November 05, 2026 | 59.81M |
| November 04, 2026 | 74.71M |
| November 03, 2026 | 75.64M |
| November 02, 2026 | 61.45M |
| October 30, 2026 | 37.20M |
| October 29, 2026 | 41.18M |
| October 28, 2026 | 42.09M |
| October 27, 2026 | 37.37M |
| October 26, 2026 | 42.05M |
| October 23, 2026 | 39.50M |
| October 22, 2026 | 44.47M |
| October 21, 2026 | 46.41M |
| October 20, 2026 | 55.66M |
| October 19, 2026 | 56.60M |
| October 16, 2026 | 57.32M |
| Date | Value |
|---|---|
| October 15, 2026 | 48.49M |
| October 14, 2026 | 34.81M |
| October 13, 2026 | 37.77M |
| October 12, 2026 | 50.43M |
| October 09, 2026 | 57.68M |
| October 08, 2026 | 58.45M |
| October 07, 2026 | 56.28M |
| October 06, 2026 | 56.79M |
| October 05, 2026 | 67.04M |
| October 02, 2026 | 62.24M |
| October 01, 2026 | 71.70M |
| September 30, 2026 | 80.41M |
| September 29, 2026 | 63.03M |
| September 28, 2026 | 65.68M |
| September 25, 2026 | 63.03M |
| September 24, 2026 | 67.79M |
| September 23, 2026 | 73.06M |
| September 22, 2026 | 81.88M |
| September 21, 2026 | 65.68M |
| September 18, 2026 | 72.82M |
| September 17, 2026 | 76.56M |
| September 16, 2026 | 80.89M |
| September 15, 2026 | 91.75M |
| September 14, 2026 | 123.16M |
| September 11, 2026 | 130.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | -72.48M |
| Context Therapeutics, Inc. | -18.71M |
| LENZ Therapeutics, Inc. | -91.90M |
| ANI Pharmaceuticals, Inc. | 1.754B |
| Corcept Therapeutics, Inc. | 6.745B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.44M |
| Total Expenses (Quarterly) | 34.44M |
| EPS Diluted (Quarterly) | -0.1833 |
| Earnings Yield | -307.2% |
| Normalized Earnings Yield | -307.18 |